Literature DB >> 14607387

Challenges in preventing relapse in major depression. Report of a National Institute of Mental Health Workshop on state of the science of relapse prevention in major depression.

Zindel V Segal1, Jane L Pearson, Michael E Thase.   

Abstract

On 21 and 22 May 2001, the National Institute of Mental Health convened a workshop to explore imminent scientific opportunities and encourage new research on preventing relapse in major depression, as a part of a larger effort to find treatments capable of producing durable long-term recovery from major depression. Participants considered definitional and developmental perspectives on depression relapse, the prophylactic potential of current treatments and their cost effectiveness and the neurobiological and psychological risk factors for episode return. It was recommended that the definition of the relapse construct be expanded to capture salient features of incomplete recovery or partial response to treatment that are associated with significant functional impairment. This information is often overlooked by the categorical criteria currently in use. With respect to interventions, there was support for sequencing pharmacological remission with psychological prophylaxis. Provision of focal, short-term treatments that embed relapse prevention skills augment the routes to effective prevention available to patients, beyond that afforded by continuation pharmacotherapy. The challenge will be to identify those subgroups of patients for whom each treatment algorithm is indicated. Finally, the link between basic science findings of biological and psychological markers of relapse vulnerability and treatment design needs to be strengthened. This could be accomplished by assessing patients in clinical prevention trials for the presence of, and changes in, relapse vulnerability markers, thereby providing direct, outcome-based data to gauge the protective value of different treatments that modify these markers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607387     DOI: 10.1016/s0165-0327(02)00112-x

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  9 in total

1.  Vitamin D and depression: where is all the sunshine?

Authors:  Sue Penckofer; Joanne Kouba; Mary Byrn; Carol Estwing Ferrans
Journal:  Issues Ment Health Nurs       Date:  2010-06       Impact factor: 1.835

Review 2.  Acupuncture for depression: a critique of the evidence base.

Authors:  Sylvia Schroer; Joy Adamson
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

Review 3.  Risk for recurrence in depression.

Authors:  Stephanie L Burcusa; William G Iacono
Journal:  Clin Psychol Rev       Date:  2007-03-03

4.  Biologic effects of mindfulness meditation: growing insights into neurobiologic aspects of the prevention of depression.

Authors:  Simon N Young
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

5.  Alcohol Use Disorder and the Persistence/Recurrence of Major Depression: Le trouble de l'usage de l'alcool et la persistance/récurrence de la dépression majeure.

Authors:  Vivian N Onaemo; Timothy O Fawehinmi; Carl D'Arcy
Journal:  Can J Psychiatry       Date:  2020-05-04       Impact factor: 4.356

6.  The long-term trajectory of depression among Latinos in primary care and its relationship to depression care disparities.

Authors:  Alejandro Interian; Alfonso Ang; Michael A Gara; Michael A Rodriguez; William A Vega
Journal:  Gen Hosp Psychiatry       Date:  2011-01-19       Impact factor: 3.238

Review 7.  Psychological Treatments for Depression in Adolescents: More Than Three Decades Later.

Authors:  Javier Méndez; Óscar Sánchez-Hernández; Judy Garber; José P Espada; Mireia Orgilés
Journal:  Int J Environ Res Public Health       Date:  2021-04-26       Impact factor: 3.390

8.  Can discrete event simulation be of use in modelling major depression?

Authors:  Agathe Le Lay; Nicolas Despiegel; Clément François; Gérard Duru
Journal:  Cost Eff Resour Alloc       Date:  2006-12-05

9.  Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial.

Authors:  Suresh Durgam; Carl Gommoll; Raffaele Migliore; Changzheng Chen; Cheng-Tao Chang; Michelle Aguirre; Michael E Thase
Journal:  Int Clin Psychopharmacol       Date:  2018-11       Impact factor: 1.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.